What it's for (Indications)
- Flunisolide is a synthetic corticosteroid primarily utilized for its potent anti-inflammatory properties in the management of specific respiratory and nasal conditions.
- Its main indications include the treatment and prophylaxis of seasonal or perennial allergic rhinitis, a common inflammatory condition of the nasal passages triggered by allergens such as pollen, dust mites, or pet dander.
- It provides effective relief from symptoms including nasal congestion, rhinorrhea (runny nose), sneezing, and nasal itching.
- Flunisolide is also indicated for the management of non-allergic rhinitis, offering symptomatic relief from chronic nasal congestion, post-nasal drip, and sneezing in cases where allergic causes have been thoroughly ruled out.
- Furthermore, flunisolide may be used for the prevention of recurrence of nasal polyps following surgical removal, helping to reduce inflammation and inhibit polyp growth in the nasal cavity.
- In some older or specific formulations, it has been indicated as a maintenance treatment for asthma as prophylactic therapy, contributing to the long-term control of asthma symptoms and reduction of exacerbations; however, it is crucial to note that flunisolide is not indicated for the relief of acute bronchospasm and should never be used as a rescue medication during an acute asthma attack.
- Its therapeutic effects are typically observed after several days of consistent use, emphasizing the importance of regular administration for optimal efficacy.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Adults: The recommended starting dose is 2 sprays (50 mcg each) in each nostril twice a day (total 200 mcg/day). This dose may be increased to 2 sprays in each nostril three times a day (total 300 mcg/day) if needed. The maximum total daily dose should not exceed 400 mcg/day (8 sprays). Pediatric Patients (6 to 14 years): The recommended starting dose is 1 spray (25 mcg each) in each nostril three times a day OR 2 sprays (50 mcg each) in each nostril twice a day (total 150 to 200 mcg/day). The maximum total daily dose for pediatric patients under 14 years of age should not exceed 200 mcg/day (4 sprays). Flunisolide Nasal Solution is not recommended for pediatric patients less than 6 years of age. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects include mild, transient nasal burning and stinging (reported in approximately 45% of patients, with a similar incidence in placebo groups, rarely leading to discontinuation).
- Other reported side effects include throat dryness, irritation, cough, nosebleeds, sneezing, and unpleasant taste.
- Consult a doctor if any of these conditions worsen.
Serious Warnings
- Black Box Warning: **Serious Warnings Regarding Systemic Corticosteroid Effects and Infection Risk** While flunisolide is primarily administered via local routes (inhalation for asthma, intranasal for allergic rhinitis) to minimize systemic absorption, prolonged use, particularly at doses exceeding recommended levels, can nonetheless lead to clinically significant systemic corticosteroid effects. A critical concern is the potential for hypothalamic-pituitary-adrenal (HPA) axis suppression. This can manifest as adrenal insufficiency, especially during periods of physiological stress (e.g., severe trauma, surgery, infection), or when patients are transitioned from systemic corticosteroids. During such vulnerable periods, patients may require supplemental systemic corticosteroids. Healthcare providers must exercise extreme caution and monitor patients closely for signs of adrenal suppression. Furthermore, corticosteroids, including flunisolide, are known to suppress the immune system, thereby masking the signs of infection and decreasing the body's resistance to new infections. Patients receiving flunisolide are at an increased risk of developing various types of infections, including local or systemic fungal, bacterial, viral, or parasitic infections. Special caution is warranted in patients with active or quiescent tuberculosis, untreated systemic fungal, bacterial, viral, or parasitic infections, or ocular herpes simplex due to the potential for exacerbation or dissemination of these conditions. Prompt and appropriate anti-infective therapy should be initiated if an infection is suspected or confirmed. These serious considerations necessitate a thorough risk-benefit assessment for each patient before and during the course of flunisolide therapy, emphasizing the importance of adherence to prescribed dosages and regular clinical follow-up.
- Pregnancy: This medication should only be used when clearly needed; consult your doctor for further advice.
- Lactation: It is unknown if this medication passes into breast milk; consult your doctor for further advice.
- Alcohol: Avoid consuming alcohol while taking this medicine.
- Precautions: Use with extreme caution in patients with recent nasal ulcers, trauma, or surgery.
- Flunisolide Nasal Solution is not recommended for pediatric patients less than 6 years of age as safety and efficacy studies, including possible adverse effects on growth, have not been conducted.
How it Works (Mechanism of Action)
Flunisolide exerts its therapeutic effects primarily through its potent anti-inflammatory and immunosuppressive actions, characteristic of glucocorticoids. Upon administration, flunisolide penetrates target cells in the nasal mucosa or airways, binding with high affinity to specific intracellular glucocorticoid receptors located in the cytoplasm. This receptor-ligand complex then undergoes a conformational change and translocates to the cell nucleus, where it interacts with specific DNA sequences known as glucocorticoid response elements (GREs) or by modulating the activity of various transcription factors such as NF-κB and AP-1. This intricate molecular interaction leads to a cascade of genomic and non-genomic effects, resulting in the upregulation of anti-inflammatory genes and the significant downregulation of pro-inflammatory genes. Specifically, flunisolide effectively inhibits the synthesis and release of a broad spectrum of inflammatory mediators, including prostaglandins, leukotrienes, histamine, and numerous cytokines (e.g., interleukins, TNF-alpha) from various inflammatory cells such as mast cells, eosinophils, neutrophils, macrophages, and lymphocytes. It also reduces capillary permeability, thereby decreasing edema, and suppresses the migration and activation of inflammatory cells into the affected tissues. In the context of nasal administration, these actions occur locally within the nasal mucosa, leading to a reduction in inflammation, swelling, and mucus production associated with rhinitis. When inhaled, these effects are localized to the airways, reducing airway hyperresponsiveness and inflammation in asthma, without significant systemic absorption at recommended therapeutic doses, thereby minimizing systemic corticosteroid side effects.